|
gptkbp:instanceOf
|
gptkb:drug
benzodiazepine
|
|
gptkbp:administeredBy
|
adults
children
|
|
gptkbp:approvalYear
|
1975
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N03AE01
|
|
gptkbp:brand
|
gptkb:Klonopin
gptkb:Rivotril
|
|
gptkbp:CASNumber
|
1622-61-3
|
|
gptkbp:chemicalClass
|
nitrobenzodiazepine
|
|
gptkbp:contraindication
|
acute narrow-angle glaucoma
severe liver disease
|
|
gptkbp:discoveredBy
|
gptkb:Hoffmann-La_Roche
|
|
gptkbp:discoveredIn
|
1960s
|
|
gptkbp:eliminationHalfLife
|
18–50 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:genericName
|
yes
|
|
gptkbp:hasMolecularFormula
|
C15H10ClN3O3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Clonazepam
|
|
gptkbp:interactsWith
|
gptkb:beer
opioids
other CNS depressants
|
|
gptkbp:isSchedule
|
Schedule IV (US)
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Roche
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor positive allosteric modulator
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:overdoseSymptoms
|
coma
respiratory depression
death (rare)
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:riskFactor
|
dependence
withdrawal symptoms
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
gptkb:depression
dizziness
fatigue
drowsiness
impaired coordination
memory impairment
|
|
gptkbp:synonym
|
5-(2-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one
|
|
gptkbp:usedFor
|
gptkb:panic_disorder
anxiety disorders
seizure disorders
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Schedule_IV
gptkb:Benzodiazepines
|
|
gptkbp:bfsLayer
|
6
|